CHANGCHUN BCHT BIOTECHNOLOGY CO. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.55 CNY | +0.05% |
|
-4.81% | -29.67% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Changchun BCHT Biotechnology Co is a China-based innovative biomedical company mainly dedicated to the prevention and treatment of infectious diseases. The Company is mainly engaged in the research and development, production and sales of human vaccines. The Company has three approved vaccine products: varicella vaccine, rabies vaccine and freeze-dried nasal spray flu vaccine. The Company also has other vaccines under development and fully human monoclonal antibody under development for the prevention and control of infectious diseases. The Company mainly conducts business within the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
38.55
CNY
Average target price
60.06
CNY
Spread / Average Target
+55.81%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.67% | 2.2B | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| +8.38% | 1.96B | |
| +3.90% | 1.65B |
- Stock Market
- Equities
- 688276 Stock
- News Changchun BCHT Biotechnology Co.
- Changchun High-Tech Industry's Unit Gets Nod to Trial Rabies Vaccine
